NEUROENDOCRINOLOGY

Estradiol Modulates Translocator Protein (TSPO) and Steroid Acute Regulatory Protein (StAR) via Protein Kinase A (PKA) Signaling in Hypothalamic Astrocytes Claire Chen, John Kuo, Angela Wong, and Paul Micevych Departments of Obstetrics/Gynecology (C.C., J.K.) and Neurobiology (A.W., P.M.), David Geffen School of Medicine at UCLA, and Laboratory of Neuroendocrinology of the Brain Research Institute (A.W., P.M.), University of California, Los Angeles, Los Angeles, California 90095

The ability of the central nervous system to synthesize steroid hormones has wide-ranging implications for physiology and pathology. Among the proposed roles of neurosteroids is the regulation of the LH surge. This involvement in the estrogen-positive feedback demonstrates the integration of peripheral steroids with neurosteroids. Within the female hypothalamus, estradiol from developing follicles stimulates progesterone synthesis in astrocytes, which activate neural circuits regulating gonadotropin (GnRH) neurons. Estradiol acts at membrane estrogen receptor-␣ to activate cellular signaling that results in the release of inositol trisphosphate-sensitive calcium stores that are sufficient to induce neuroprogesterone synthesis. The purpose of the present studies was to characterize the estradiol-induced signaling leading to activation of steroid acute regulatory protein (StAR) and transporter protein (TSPO), which mediate the rate-limiting step in steroidogenesis, ie, the transport of cholesterol into the mitochondrion. Treatment of primary cultures of adult female rat hypothalamic astrocytes with estradiol induced a cascade of phosphorylation that resulted in the activation of a calcium-dependent adenylyl cyclase, AC1, elevation of cAMP, and activation of both StAR and TSPO. Blocking protein kinase A activation with H-89 abrogated the estradiol-induced neuroprogesterone synthesis. Thus, together with previous results, these experiments completed the characterization of how estradiol action at the membrane leads to the augmentation of neuroprogesterone synthesis through increasing cAMP, activation of protein kinase A, and the phosphorylation of TSPO and StAR in hypothalamic astrocytes. (Endocrinology 155: 2976 –2985, 2014)

stradiol (E2) signaling plays a central role in the regulation of the hypothalamo-pituitary-ovarian axis. During most of the estrous cycle, E2 negatively feeds back onto the hypothalamus, preventing the surge release of GnRH. On proestrus, however, rising levels of E2 indirectly and positively signal the release of GnRH, stimulating the LH surge and subsequent ovulation (1). The rising levels of E2 also stimulate neuroprogesterone synthesis in the hypothalamus, a critical step modulating estrogen positive feedback and ovulation (2, 3). Blocking steroidogenesis in the hypothalamus of E2-treated ovariectomized and adrenalectomized rats or in gonadally in-

E

tact rats prevents the LH surge (2, 4 – 6). Astrocytes are the most steroidogenic cells in the nervous system, and E2 stimulates neuroprogesterone synthesis in hypothalamic astrocytes (7–9). The E2 facilitation of neuroprogesterone synthesis requires membrane estrogen receptor-␣ (ER␣) and the transactivation of metabotropic glutamate receptor-1a (mGluR1a), which induces a robust elevation of intracellular free calcium ([Ca2⫹]i) through the phospholipase C generation of inositol trisphosphate (IP3) (10, 11). The release of calcium (Ca2⫹) is necessary for neuroprogesterone synthesis (Figure 1) (10, 12, 13), but preliminary results indicated that E2 treatment of astrocytes induces

ISSN Print 0013-7227 ISSN Online 1945-7170 Printed in U.S.A. Copyright © 2014 by the Endocrine Society Received September 10, 2013. Accepted May 20, 2014. First Published Online May 30, 2014

Abbreviations: AC1, adenylyl cyclase-1; 2-APB, 2-aminoethoxydiphenyl borate; Ct, comparative threshold cycle; CYP11A1, cytochrome p450 side-chain cleavage enzyme; E2, estradiol; ER␣, estrogen receptor-␣; FBS, fetal bovine serum; IP3, inositol trisphosphate; mGluR1a, metabotropic glutamate receptor-1a; PKA, protein kinase A; SNK, StudentNewman-Keuls; StAR, steroid acute regulatory protein; TSPO, translocator protein.

2976

endo.endojournals.org

Endocrinology, August 2014, 155(8):2976 –2985

doi: 10.1210/en.2013-1844

The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 22 March 2015. at 19:22 For personal use only. No other uses without permission. . All rights reserved.

endo.endojournals.org

IC

I1

82

,7

80

doi: 10.1210/en.2013-1844

ERα

mGluR1a LY367,385 Gαq

PLC U-73122 IP3R 2-APB AC1 NB001 PKA

H-89 pStAR

H-89 pTSPO

Figure 1. A schematic of the pathway leading to the activation of TSPO in astrocytes. Estradiol activates ER␣, transactivating mGluR1a and stimulating the release of internal stores of Ca2⫹ from IP3 receptor-sensitive stores. This [Ca2⫹]i activates AC1, generating cAMP to stimulate PKA, phosphorylating StAR and TSPO, and facilitating the import of cholesterol into the mitochondrion. Here, CYP11A1 cleaves the side chain producing pregnenolone, which is converted to progesterone by 3␤-hydroxysteroid dehydrogenase either in the mitochondrion or the smooth endoplasmic reticulum. The inhibitors are listed below each step.

protein kinase A (PKA). The present experiments were done to characterize the pathway through which E2 action at the membrane modulates the rate-limiting step of steroidogenesis, that is, the transport of cholesterol to the inner mitochondrial membrane. In classical steroidogenic tissue (eg, ovary and adrenal) as well as astrocytes, translocator protein (TSPO; also known as peripheral-type benzodiazepine receptor) appears to interact with steroid

2977

acute regulatory protein (StAR) to mediate this cholesterol transport function (14, 15) (but see Ref. 16). In vivo, a microarray of phosphorylated proteins indicated that E2 treatment activated both PKC and PKA in hypothalamic tissue (17). Although both kinases have been reported to increase the activity of TSPO and StAR initiating steroid biosynthesis, it is not clear which pathway is involved in astrocytes (18 –20). The Ca2⫹ dependence of neuroprogesterone synthesis suggests that a PKC mechanism is principally involved in this regulation. However, PKA has been shown to be the primary modulator of StAR and TSPO activity (21–23). Thus, in the present experiments, we need to understand the role of E2-induced [Ca2⫹]i in the regulation of PKC or PKA activation and neuroprogesterone synthesis. Using primary cultures of postpubertal female hypothalamic astrocytes, we determined that E2 stimulated phosphorylation of StAR and TSPO by PKA and that blocking PKA activation abrogated the synthesis of neuroprogesterone. Estradiol treatment activated PKA through a Ca2⫹-dependent adenylyl cyclase-1 (AC1) (24, 25), which increased levels of cAMP. Antagonizing IP3 receptors prevented the E2-induced phosphorylation of PKA. Interestingly, we did not detect an E2 induction of PKC␪ in astrocytes, whereas we had measured such an increase in neurons (17, 26, 27). Antagonizing PKA blocked the E2-induced neuroprogesterone synthesis while also preventing the activation of TSPO and StAR. Together with previous results from our laboratory, the present results indicate that the E2 control of the ratelimiting step in neuroprogesterone synthesis in astrocytes requires induction of a pathway from membrane ER␣ to IP3 receptor-dependent Ca2⫹ release and stimulation of AC1. The increased intracellular level of cAMP increased PKA phosphorylation and activated StAR and TSPO to facilitate cholesterol transport to the mitochondrial inner membrane increasing steroidogenesis (Figure 1). Some of these results have been presented earlier in preliminary form (28).

Materials and Methods All experimental procedures were performed in accordance with the principles and procedures of the National Institutes of Health Guide for the Care and Use of Laboratory Animals and approved by the Chancellor’s Animal Research Committee at the University of California at Los Angeles.

Primary cell culture Primary hypothalamic astrocyte cultures were prepared from 4 to 6 Long-Evans female rats (40 –50 days old) (Charles River) as described previously (12, 13, 29). Briefly, hypothalamic

The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 22 March 2015. at 19:22 For personal use only. No other uses without permission. . All rights reserved.

2978

Chen et al

Estradiol Regulates StAR and TSPO

blocks were dissected with the following boundaries: rostral extent of the optic chiasm, rostral extent of the mammillary bodies, lateral edges of the tuber cinereum, and the top of the third ventricle. The tissue was minced, dissociated by mechanical and enzymatic treatment with 2.5% trypsin solution (Invitrogen), and plated in T-75 flasks. Cultures were maintained at 37°C with 5% CO2 and grown in DMEM/F12 (Mediatech), supplemented with 20% fetal bovine serum (FBS) (Invitrogen), 1% penicillin (10 000 IU/mL)/streptomycin (10 000 ␮g/mL) solution (Mediatech), and 2.5mM L-glutamine (Hyclone) for 3 days before the medium was replaced. After 12 days, FBS was decreased to 10%. Astrocyte cultures were grown to confluence and shaken on an orbital shaker at 200 rpm at 37°C for 18 to 24 hours to eliminate oligodendrocytes and microglia (30). For quantitative real-time PCR (RT-PCR), 200 000 cells per well were replated into 6-well plates. Before experimental manipulations, astrocytes were steroidstarved for 18 to 24 hours with 5% charcoal-stripped FBS in DMEM/F12 medium. Cultures were then treated with vehicle dimethylsulfoxide or 17␤-estradiol (10⫺9M–10⫺7M; Sigma-Aldrich) in steroid-free media (see above) for 20 minutes, 24 hours, or 48 hours at 37°C. Cells were collected for immunoblotting and quantitative RT-PCR after E2 treatment.

Endocrinology, August 2014, 155(8):2976 –2985

ferred onto polyvinylidene fluoride membranes through a semidry transfer procedure (Bio-Rad). For detection of phospho-proteins, phosphoprotein-binding resin columns (Thermo Fisher Scientific) were used when antibodies were not available or effective. Membranes were probed with primary rabbit polyclonal antibodies: TSPO (1:1000; Trevigen, Inc), StAR (1:1000; Abcam), phospho-PKA (Thr197) (1:500; Cell Signaling), phosphoPKC (Thr538) (1:500; Cell Signaling), PKA (1:1000; Cell Signaling), PKC (1:1000; Cell Signaling), and AC1 (ab38331; Abcam). All antibodies were diluted in 5% nonfat dry milk or 5% bovine serum albumin in Tris-buffered saline/Tween 20 (0.1% [vol/vol]) according to the suppliers’ recommendations. Blots were then incubated with goat antirabbit IgG horseradish peroxidase (1:10,000; Santa Cruz Biotechnology, Dallas, TX), or goat antirabbit IgG (H⫹L) (1:10,000; Vector Laboratories) for 1 hour at room temperature. Bands were visualized using an enhanced chemiluminescence (ECL) kit (Thermo Fisher Scientific). ␤-Actin (1:1000; Cell Signaling) was used as a loading control, and immunoreactive bands were normalized to obtain the percentage of protein to ␤-actin ratio. Bands were immediately visualized using FluorChem E and analyzed by Alphaview software (Cell Bioscience).

cAMP ELISA Quantitative RT-PCR analysis To determine the E2 regulation of TSPO, we initially tested whether E2 increased the levels of TSPO mRNA. The mRNA levels were measured in postputbertal female rat hypothalamic astrocytes by quantitative RT-PCR. Briefly, total RNA was isolated from primary astrocyte cultures using TRIZOL reagent (Invitrogen) according to the manufacturer’s protocol. Total RNA was quantified using a NanoDrop ND-1000 spectrophotometer (Thermo Scientific). cDNA was synthesized from the total cellular RNA using random hexamers and Superscript III RNase H reverse transcriptase (Invitrogen). Quantitative realtime PCRs were performed in the Mx3000P real-time PCR system (Agilent) using TaqMan gene expression assays (Applied Biosystems) for TSPO (assay ID RN00560892_m1). The primers in this gene expression assay amplified a 117-bp region spanning exons 3 and 4 (accession no. NM_012515.2). The PCR conditions used for amplification were an initial setup for 2 minutes at 50°C and 10 minutes at 95°C, denaturation for 15 seconds at 95°C, and annealing for 1 minute at 60°C for 60 cycles. Samples were run in duplicate. Negative controls, without reverse transcriptase, and water controls were included in each reaction. Relative gene expression data were analyzed using the comparative threshold cycle (Ct) method (31). The Ct values of TSPO mRNA level were normalized to the endogenous gene GAPDH mRNA level present within each sample well.

Immunoblotting For Western blotting, astrocyte cultures (1 T-75 flask per treatment) were washed 3 times with HEPES buffer and collected by mechanical scraping (Corning). The samples were centrifuged (1800 rpm for 5 minutes), and the cell pellets were lysed in Lysis M buffer (Roche) with protease inhibitor and phosphatase inhibitor (Invitrogen). Protein concentrations were determined using the bicinchoninic acid method. Protein (30 ␮g) of each sample was loaded on a 10% SDS or Any KD polyacrylamide gel (Bio-Rad) and separated by electrophoresis. Proteins were trans-

Cells were replated onto 6-well plates and steroid-starved for 18 hours as indicated above. After steroid starvation, cells were incubated with 250mM 3-isobutyl-1-methylxanthine (Sigma) for 30 minutes to inhibit cAMP-metabolizing phosphodiesterases. Cells were pretreated with vehicle or 100␮M NB001 (AC1 inhibitor; Sigma-Aldrich) for 15 minutes before the 20minute vehicle or 1nM E2 treatment in steroid-free media. Cells were washed once with ice-cold Hank’s Balanced Salt Solution and lysed in 0.1N HCl, 0.5% Triton X-100. Lysates were clarified with centrifugation at 10 000g for 5 minutes. Intracellular cAMP levels were quantified from the supernatants using the cAMP complete ELISA kit (Enzo Life Sciences) according to the manufacturer’s instructions using the acetylation protocol. Interassay coefficients of variation were between 4.6% and 8.4%, and intra-assay coefficients of variation were between 7.8% and 13.6% for the acetylated version of the assay according to the manufacturer. ELISA data were normalized to protein concentrations of the lysates.

Progesterone RIA Astrocytes (500 000) were plated into 6-well culture plates and grown for 24 hours. Astrocytes were then steroid-starved for 18 hours before experimentation. After the 18-hour steroid starvation, culture medium was removed, 1 mL of H-89 (100␮M) was added to each well and incubated for 5 minutes, the supernatant was collected, and the samples were frozen at ⫺4°C. For RIA, samples were thawed, mixed with diethyl ether (Fisher Scientific), vortexed for 2 minutes, and placed into a methanol and dry ice bath to freeze the aqueous layer. The upper ether layer was decanted into a separate tube, and the ether was allowed to evaporate overnight. The extract was reconstituted in isooctane (Mallinkrodt Baker) and a Celite column (Sigma-Aldrich) with ethylene glycol as the stationary phase used to isolate the progesterone. Progesterone was then eluted off the column using 4 mL of isooctane. Standards and samples (100 ␮L) were incubated with rabbit polyclonal antibody against progesterone (Sig-

The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 22 March 2015. at 19:22 For personal use only. No other uses without permission. . All rights reserved.

doi: 10.1210/en.2013-1844

endo.endojournals.org

A

2979

Statistical analysis

*

p-PKA

42 kDa

PKA

42 kDa

-actin

45 kDa

p-PKA/PKA (% of Control)

180

*

160 140 120 100 80 60 40 20 0 Control

B

p-PKC /PKC (% of Control)

120 100

p-PKC

79 kDa

PKC

80 kDa

-actin

45 kDa

1 nM E2

10 nM E2

100 nM E2

Data are presented as means ⫾ SEM of a percent relative ratio. Statistical comparisons were made using unpaired Student’s t test when comparing means between 2 independent groups, and oneway ANOVA with Student-NewmanKeuls (SNK) post hoc test when comparing means across 3 or more independent groups. Values of P ⬍ .05 were considered significant. For RT-PCR, the relative difference between sample groups was calculated according to the difference in Ct values using 2⫺⌬(⌬ Ct) (31).

80 60

Results

40 20

In primary hypothalamic astrocyte cultures derived from postpubertal Control 10 nM E2 100 nM E2 1 nM E2 female rats, E2 treatment induced the Figure 2. Effect of E2 on phosphorylation of PKA in primary cultures of astrocytes obtained PKA pathway (Figure 1). A 20-minfrom postpubertal female rats. All doses of E2 activated PKA, but not PKC␪. Vehicle control (no E2) was set as 100%. The other cultures were treated with E2 for 20 minutes. In B, values ute treatment with either 1nM or represent means (n ⫽ 5 independent experiments) ⫾ SEM of relative ratio normalized to the 100nM E2 increased PKA phosphorvehicle control (no E2) that was set as 100%. *, Significant difference from controls (P ⬍ .05) as ylation levels by 30% to 40% (Figure determined by one-way ANOVA with SNK post hoc test. 2A; 1nM E2: 130.59% ⫾ 5.01%, ma-Aldrich) for 30 minutes at 37°C. Tritium-radiolabeled pro100nM E2: 143.72% ⫾ 13.23% vs control; one-way gesterone (2000 cpm/mL) was then added and incubated for an ANOVA; df ⫽ 3, 36; F ⫽ 4.161; SNK P ⬍ .05). Because additional 60 minutes at 37°C. Standards and samples were E 2 has been demonstrated to activate PKA and PKC␪ in the cooled at 4°C, and a 0.05% charcoal dextran solution (Sigmahypothalamus in vivo (16), we also measured the E2 inAldrich) was added to remove all unbound progesterone. The mixture was centrifuged (3000 rpm) for 15 minutes at 4°C. All duction of phospho-PKC␪ in vitro (Figure 2). Treatment samples were run in duplicate, and sample progesterone concenwith 1nM, 10nM, or 100nM E2 did not increase levels of trations determined by extrapolation from a curve determined phosphorylated PKC␪ (Figure 2B; 94.17% ⫾ 11.34% vs from the progesterone standards. The intra- and interassay cocontrol; one-way ANOVA; df ⫽ 3, 19; F ⫽ 2.041; SNK efficients of variation for progesterone were 3.2% and 4.8%, P ⬎ .05). respectively. PKA is activated by cAMP generated by adenylyl cyclase. Because a A B hallmark of E2 action in astrocytes is 10 the elevation of [Ca2⫹]i, we investi* gated whether E2 induced the Ca2⫹8 AC1 124 kDa dependent AC1. Primary astrocyte 6 45 kDa β-actin cultures were stimulated with E2 for 20 minutes, harvested, and pro4 140 cessed for Western blotting. Estra120 2 diol treatment did not significantly 100 80 increase AC1 levels (Figure 3; 0 60 Control E2 121.6% ⫾ 9.7% vs control; un40 paired t test df ⫽ 6; P ⫽ .0657, t ⫽ 20 ⫺4.671), but cAMP levels were sig0 Control E2 nificantly increased (Figure 3B; E2: 6.53 ⫾ 1.07 pmol cAMP/mg protein Figure 3. E2 treatment increased cAMP in primary astrocyte cultures. A, Whole-cell lysates were then separated and identified with Western blotting. E2 (1nM) did not induce Ca2⫹-dependent vs control: 2.78 ⫾ 0.50 pmol AC1 activity. B, E2 (1nM) increased intracellular cAMP levels more than 2-fold as determined by a cAMP/mg protein; unpaired t test competitive ELISA for cAMP. Values represent means ⫾ SEM. *, P ⬍ .05, as determined by df ⫽ 8; P ⫽ .013, t ⫽ ⫺3.173). To unpaired Student’s t test of 4 independent experiments. cAMP (pmol/mg protein)

AC1 (% of Control)

0

The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 22 March 2015. at 19:22 For personal use only. No other uses without permission. . All rights reserved.

2980

Chen et al

Estradiol Regulates StAR and TSPO

Endocrinology, August 2014, 155(8):2976 –2985

NB001 plus E2: 94.78% ⫾ 8.55%; one-way ANOVA df ⫽ 3, 12; F ⫽ 160 * 11.732; SNK P ⬍ .01). 140 E2 treatments for various times 120 (20 minutes, 24 hours, or 48 hours) 100 did not increase TSPO mRNA levels 42 kDa p-PKA (one-way ANOVA df ⫽ 3, 15; F ⫽ 80 1.563; SNK P ⬎ .05; data not 60 shown). These results indicate that 42 kDa PKA 40 TSPO was not regulated through a 20 transcriptional mechanism. To ex0 amine whether TSPO was phosphorβ-actin 45 kDa NB001 NB001 Control E2 E2 (1 nM) ylated in response to E2 treatment, astrocyte cultures were harvested, Figure 4. Inhibition of AC1 abolished PKA phosphorylation. Cultures of postpubertal hypothalamic astrocytes were pretreated for 15 minutes with NB001 (an AC1 inhibitor) or vehicle and whole-cell lysates passed and then treated with 1nM E2 or vehicle for 20 minutes. Stimulation with E2 alone induced PKA through a phosphoprotein-binding phosphorylation, whereas treatment with NB001 plus E2 prevented PKA activation. Values are resin column. Retained phosphorymeans ⫾ SEM of relative ratio normalized to the vehicle control (no NB001, no E2) set as 100%. lated proteins were eluted and ana*, P ⬍ .05, as determined by one-way ANOVA with SNK post hoc test. lyzed by Western blotting using a demonstrate that E2-induced activation of PKA depended TSPO-specific antibody. At 20 minutes, 1nM E treatment 2 on AC1, astrocyte cultures were incubated with NB001, produced a 70% increase in intracellular levels of phosan AC1 inhibitor (100␮M; Sigma-Aldrich), or vehicle (di- phorylated TSPO (Figure 5A; 170.18% ⫾ 12.65% vs conmethylsulfoxide) before E2 treatment. E2 exposure signif- trol; unpaired t test df ⫽ 8; P ⫽ .0005, t ⫽ ⫺5.550). icantly elevated phospho-PKA levels, and this increase was Because StAR mRNA is not increased by E treatment in 2 abrogated by NB001 (Figure 4; E2: 141.12% ⫾ 3.96% vs vitro (32), we examined whether phosphorylation of StAR was regulated by membrane-initiated E2 signaling. Like TSPO, 1nM 200 180 E2 treatment increased levels of A 160 phosphorylated StAR (Figure 5B; 140 120 138.55% ⫾ 4.28% vs control; un100 paired t test df ⫽ 8; P ⬍ .0001, t ⫽ 80 p-TSPO 18 kDa 9.009). 60 40 E2 induces a robust increase in 20 2⫹ β-actin 45 kDa [Ca ]i in primary astrocytes, and 0 Control 1 nM E2 this increase is necessary for neuroprogesterone synthesis (10, 11). To B 200 test the role of activating IP3 recep180 160 tors in PKA activation, astrocytes 140 were treated with the IP3 receptor in120 hibitor 2-aminoethoxydiphenyl bo37 kDa p-StAR 100 rate (2-APB; 5␮M), 5 minutes before 80 60 E2 stimulation. 2-APB inhibited E2-actin 45 kDa 40 induced PKA phosphorylation (Fig20 ure 6; E2: 137.97% ⫾ 14.75% vs 0 Control 1 nM E2 2-APB plus E2: 86.91% ⫾ 6.43%; Figure 5. The effect of E2 on phosphorylation of TSPO and StAR in hypothalamic astrocytes. one-way ANOVA df ⫽ 3, 12; F ⫽ Astrocyte cultures were incubated with 1nM E2 for 20 minutes. After E2 treatment, 7.909; SNK P ⫽ .0036). phosphorylated proteins were isolated from whole-cell lysates using a phosphoprotein-binding To determine whether E2-inresin column and analyzed by immunoblotting. Phospho-TSPO and phospho-StAR were normalized to ␤-actin. A, E2 treatment increased TSPO phosphorylation by 70% (n ⫽ 5 duced PKA-regulated TSPO and independent experiments). B, E2 treatment increased StAR phosphorylation by 40% (n ⫽ 4 StAR activity, hypothalamic astroindependent experiments); cytoplasmic, active phospho-StAR was observed at 37 kDa. Vehicle cyte cultures were treated with a control (no E2) was set as 100%. Values are means ⫾ SEM. *, P ⬍ .05, as determined by unpaired Student’s t test. PKA inhibitor, N-[2-[[3-(4-bro-

A

p-StAR (% of Control)

p-TSPO (% of Control)

p-PKA/PKA (% of Control)

B

*

*

The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 22 March 2015. at 19:22 For personal use only. No other uses without permission. . All rights reserved.

doi: 10.1210/en.2013-1844

endo.endojournals.org

p-PKA

42 kDa

PKA

42 kDa

β-actin

45 kDa

p-PKA/PKA (% of Control)

* 160 140 120 100 80 60 40 20 0

2-APB

2-APB +E2

Control

E2 (1 nM)

2981

bertal astrocyte enriched cultures were treated with a PKA inhibitor, H-89, in the presence or absence of E2. H-89 blocked estradiol-induced progesterone synthesis (Figure 8; df ⫽ 3,12; F ⫽ 13.2; P ⬍ .001).

Discussion

Figure 6. Inhibition of IP3 receptor abolished PKA phosphorylation. Postpubertal hypothalamic astrocytes were incubated with IP3 receptor inhibitor 2-APB before E2 stimulation, and the effect of 2-APB on PKA phosphorylation were determined. 2-APB significantly blocked the E2-induced cAMP-PKA signaling (n ⫽ 4 independent experiments). Values are means ⫾ SEM of relative ratio normalized to the vehicle control (no 2-APB, no E2) set as 100%. *, P ⬍ .05, as determined by one-way ANOVA with SNK post hoc test.

p-StAR (% of Control)

p-TSPO (% of Control)

Previous studies have demonstrated that the E2-induced increase of neuroprogesterone synthesis in hypothalamic astrocytes is rapid and does not appear to be dependent on de novo gene transcription (12, 32). mophenyl)-2-propenyl-]amino]ethyl]-5-isoquinolineSeveral observations are consistent with this idea, includsulfonamide dihydrochloride (H-89; 25␮M). A 30-mining E membrane-induced signaling and the release of in2 ute pretreatment with H-89 prevented E2 induction of 2⫹ tracellular stores of Ca . Release of Ca2⫹ without E2 TSPO phosphorylation (Figure 7A; E2: 148.07% ⫾ 4.98% of control vs H-89 plus E2: 85.93% ⫾ 7.39%; stimulation was sufficient to increase neuroprogesterone one-way ANOVA df ⫽ 3, 16; F ⫽ 60.366; SNK P ⬍ synthesis in astrocytes (32) and suggested that this facili.0001). Similarly, H-89 inhibited StAR phosphorylation tation required an increased transport of cholesterol into (Figure 7B; E2: 138.55% ⫾ 4.28% vs H-89 plus E2: the mitochondrion. This is the rate-limiting step of ste91.18% ⫾ 9.56%; one-way ANOVA df ⫽ 3, 14; F ⫽ roidogenesis and is mediated by the transport proteins 29.419; SNK P ⬍ .0001). Together these data suggest that TSPO and StAR. Thus, the major findings of these studies a PKA-mediated mechanism activated TSPO and StAR, are that the E2-induced synthesis of neuroprogesterone in female hypothalamic astrocytes is regulated by the PKA inducing cholesterol transport. To ascertain whether blocking PKA disrupted estradi- pathway, probably through activation of StAR and TSPO. ol-induced progesterone synthesis in astrocytes, postpu- StAR is a hormone-induced protein that is targeted to the mitochondrion and is critical for A TSPO-mediated intracellular lipid 160 transport into the mitochondrial ma* 140 trix (21, 33). Here, along the inner 120 mitochondrial membrane, choles100 p-TSPO 18 kDa 80 terol is converted to pregnenolone by 60 β cytochrome P450 side-chain cleav45 kDa 40 age enzyme (CYP11A1), the first en20 0 zymatic step of steroid biosynthesis. Control H-89 H-89 E2 +E2 (1 nM) The present results bring together B 160 disparate observations about E2 ac* 140 tion in astrocytes and the synthesis 120 of neuroprogesterone. First, E2-in100 duced release of IP3-sensitive stores 80 p-StAR 37 kDa 60 of Ca2⫹, which we showed was nec40 β-actin 45 kDa essary for the generation of cAMP 20 needed for PKA phosphorylation. 0 Control H-89 H-89 E2 Second, E2 activation of PKA was +E2 (1 nM) necessary for phosphorylation of Figure 7. Inhibition of PKA prevented TSPO and StAR phosphorylation. Postpubertal StAR and TSPO. Blocking PKA prehypothalamic astrocyte cultures were pretreated with PKA inhibitor H-89, followed by a 20minute E2 treatment. A, H-89 significantly prevented TSPO phosphorylation (n ⫽ 5 independent vented E2-induced neuroprogesterexperiments). B, H-89 significantly inhibited StAR phosphorylation (n ⫽ 4 independent one synthesis. This is similar to the experiments). Values are means ⫾ SEM of relative ratio normalized to the vehicle control (no Hhormone-stimulated phosphoryla89, no E2) set as 100%. *, P ⬍ .05, as determined by one-way ANOVA with SNK post hoc test.

The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 22 March 2015. at 19:22 For personal use only. No other uses without permission. . All rights reserved.

2982

Chen et al

Estradiol Regulates StAR and TSPO

*

progesterone (pg/mL)

50 40 30 20 10 0 DMEM

H-89

H-89

E2 (1nM)

Figure 8. Effect of H-89, a PKA inhibitor, on E2-induced neuroprogesterone synthesis in postpubertal astrocytes in vitro. Astrocytes had a robust facilitation of neuroprogesterone synthesis upon exposure to E2 (1nM; P ⬍ .05 vs DMEM control). H-89 by itself did not significantly reduce basal neuroprogesterone synthesis in female astrocytes (P ⬎ .05 vs control). Treatment of astrocytes with H-89 prevented the E2-stimulated neuroprogesterone synthesis (P ⬎ .05 vs control). Values are means of 6 samples ⫾ SEM. *, Significant difference (P ⬍ .05 compared with control [DMEM] determined by one-way ANOVA with SNK post hoc test).

tion of StAR and TSPO in various steroidogenic cells that has been has been well studied (34, 35). But to our knowledge, this is the first report in astrocytes to demonstrate the pathway through which E2 membrane-initiated signaling led to activation of StAR and TSPO and a rapid facilitation of neuroprogesterone synthesis. In vivo, E2-induced neuroprogesterone synthesis is critical for stimulating the LH surge and ovulation in rodents (reviewed in Ref. 36). Blocking steroidogenesis in rodent hypothalamus prevents estrogen positive feedback and ovulation (2, 5). Moreover, these results are consistent with the action of mifepristone in women taking oral contraceptives and suggest that extraovarian progesterone synthesis is required for the LH surge in humans (37). Although astrocytes from other regions are capable of synthesizing progesterone, only postpubertal astrocytes derived from the female hypothalamus are capable of responding to E2 with elevated synthesis (2, 13). Consistent with this observation, male rodents do not exhibit an estrogen positive feedback-induced LH surge (2, 38). As with estrogen positive feedback, the E2 facilitation of neuroprogesterone synthesis in hypothalamic astrocytes is sexually differentiated through gonadal steroid action during development (38). Treatment of female primary adult astrocytes with E2, in vitro, rapidly elicits a dramatic increase in [Ca2⫹]i, which facilitates neuroprogesterone synthesis (32). This release of intracellular stores of Ca2⫹ is mediated by mem-

Endocrinology, August 2014, 155(8):2976 –2985

brane ER␣ transactivating the mGluR1a and the generation of IP3 (12). It had not been clear how this fit with the observed E2 regulation of levels of TSPO ligand binding and TSPO mRNA (39 – 42). Moreover, an analysis of the amino acid sequence of the rat TSPO gene revealed the presence of several putative phosphorylation sites (43). In peripheral tissues, PKA phosphorylates TSPO, and this phosphorylation is dependent on cAMP (34). The present experiments defined a pathway from membrane-initiated E2 release of Ca2⫹ to increased cAMP and the activation of PKA. The key findings are that blocking AC1 or PKA activation prevented TSPO and StAR activation, and blocking PKA prevents E2-induced neuroprogesterone synthesis, which is consistent with the report of PKA-mediated TSPO phosphorylation (33). We observed differences between the effects of E2 treatment of primary cultures of postpubertal astrocytes compared with the in situ hypothalamic response to E2. In vivo, E2 induces the transcription of 3␤-hydroxysteroid dehydrogenase (HSD3B1), an enzyme critical to steroidogenesis, but not StAR or CYP11A1 (44). In astrocyte cultures, however, we did not detect any change in the mRNA levels of steroidogenesis-associated proteins (32). Similarly, in the present study, TSPO mRNA was not increased. Although E2 may regulate TSPO transcription through an estrogen response element, the acute increase of steroidogenesis in astrocytes requires a different mechanism (32, 42). By demonstrating that E2 induced PKA, the present experiments uncover the mechanism by which E2 membrane-initiated signaling facilitates neuroprogesterone synthesis (Figure 1). Before these experiments, and based on the E2-induced increase in [Ca2⫹]i, we assumed that stimulation of neuroprogesterone synthesis in astrocytes was associated with PKC. In neurons, E2 induces PKC␪ phosphorylation, an action that activates sexual receptivity (17). In distinction to neurons, astrocytes had an E2-induced increase in [Ca2⫹]i, stimulating a Ca2⫹-sensitive AC1 and resulting in elevated cAMP levels and activating PKA. StAR appears critical for the acute regulation of steroidogenesis along with TSPO (45). The amino acid sequence of StAR contains 2 consensus sequences for PKA phosphorylation sites. In particular, a phosphorylation site at serine 194/195 mediated by PKA allows StAR to become fully active, allowing its insertion into the mitochondrial membrane (46). The present results are consistent with the proposed mechanism of hormonally induced steroidogenesis, which needs very rapid phosphorylation and activation of StAR and TSPO, to facilitate the transport of cholesterol to the inner mitochondrial membrane where CYP11A1 cleaves the cholesterol side chain forming pregnenolone (47). The interaction of StAR and TSPO

The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 22 March 2015. at 19:22 For personal use only. No other uses without permission. . All rights reserved.

doi: 10.1210/en.2013-1844

in the mitochondrial membrane was revealed by fluorescent resonance energy transfer analysis (48). In MA-10 Leydig cells, hormone stimulation induced the colocalization of TSPO, PKA regulatory subunit RI␣-associated protein 7 (PAP7), and StAR in mitochondria (21). Inhibition of StAR and TSPO abrogate the hormonally induced progesterone synthesis (49). In astrocytes, the described PKAmediated mechanism allows for the rapid facilitation of neuroprogesterone synthesis, which can be measured within minutes of E2 treatment (12). The described phosphorylation cascade fits the time course of this rapid activation of already existing proteins leading to phosphorylation of StAR and TSPO. The 37-kDa precursor of StAR is a cytoplasmic protein and has an NH2-terminal mitochondrial-targeting sequence. Phosphorylation activates StAR and facilitates cholesterol transport. The importation of the 37-kDa StAR into the mitochondrion results in cleavage to a 32kDa intermediate and eventually to the mature, inactive 30-kDa intramitochondrial protein (47, 49 –53). Upon hormonal stimulation, StAR-expressing cells convert cholesterol to pregnenolone, suggesting that StAR is involved in rapid steroidogenesis (54). We and several others have identified StAR in the brain and in particular in astrocytes (32, 44, 55–57). cAMP upregulated StAR expression in mesencephalic and cerebellar astrocytes, which increased pregnenolone synthesis after 12 to 24 hours (58), but in our experiments, the time course was much more rapid, 5 to 60 minutes (13, 32). TSPO was originally discovered as a binding site for the benzodiazepines in peripheral tissue, hence its original name, peripheral benzodiazepine receptor (PBR) (59, 60). The cholesterol recognition amino acid consensus (CRAC) domain of TSPO appears to be responsible for the mitochondrial uptake and translocation of cholesterol (61, 62). Not surprisingly, the most studied role of TSPO is in steroidogenesis (15). Agonists of TSPO stimulate steroidogenesis in both peripheral tissues and in the brain, and knockdown of TSPO abrogates steroidogenesis (63, 64). However, TSPO functionality requires the interaction with several mitochondrial membrane proteins that form a 140- to 220-kDa complex consisting of the voltage-dependent anion channel (VDAC1), adenine nucleotide transporter (ANT), diazepam-binding inhibitor (acyl-coenzyme A-binding domain 1, ACBD1), the TSPO-associated protein-1 (PRAX-1), and the PKA regulatory subunit RI␣-associated protein 7 (PAP7) (45, 65). This multiprotein complex is downstream of, and regulated by, StAR (21, 49), which can be demonstrated by the highly attenuated, but still extant, steroidogenesis in the absence of StAR (66, 67).

endo.endojournals.org

2983

Although our laboratory’s focus is on the regulation of reproduction, and particularly on central nervous system control of the LH surge, the present findings have salience to a wide range of actions in which neurosteroids and TSPO have been implicated, including apoptosis, differentiation, neuroprotection (encompassing neurodegenerative, ischemic, and traumatic insults), cognition, and anxiolysis (42). The role of steroidogenesis in the nervous system has been reported to be both deleterious and beneficial. Recently, TSPO has been implicated in several central nervous system pathologies. In a model of multiple sclerosis, TSPO is upregulated in microglia and astrocytes during neural inflammation. Significantly, TSPO downregulation has been shown to be beneficial for MS (68). However, in rat models of axotomy and neuropathy, TSPO ligands improved neural survival and repair, suggesting that TSPO-mediated steroidogenesis could be a potential treatment for neurodegenerative diseases (69). In the 3xTgAD mouse model of Alzheimer’s disease, TSPO activation was shown to enhance steroidogenesis and neuroprotection (70). Moreover, activation of TSPO has been shown to have anxiolytic actions potentially due to an increase in synthesis of neurosteroids with sedative properties (64, 71, 72). Patients with posttraumatic stress disorder have lower levels of TSPO, and stimulation of TSPO improved behavioral deficits in a mouse model of posttraumatic stress disorder (73–75). In summary, the present results have mapped the pathway of E2-induced facilitation of neuroprogesterone synthesis, which involves the release of intracellular Ca2⫹ stores, elevating cAMP levels, activating PKA and the phosphorylation of both StAR and TSPO, stimulating the transport of cholesterol into the mitochondrial matrix, and increasing the synthesis of progesterone.

Acknowledgments We gratefully acknowledge the editorial comments of Dr Melinda Mittelman-Smith. Address all correspondence and requests for reprints to: Paul Micevych, PhD, Department of Neurobiology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095–1763. E-mail: [email protected] The research was supported by National Institutes of Health Grant HD042635 to P.M. Disclosure Summary: The authors have nothing to disclose.

References 1. Herbison A. Physiology of the gonadotropin-releasing hormone neuronal network. In: Neill J, ed. Physiology of Reproduction, 3rd Ed. Burlington, MA: Elsevier; 2006:1415–1482.

The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 22 March 2015. at 19:22 For personal use only. No other uses without permission. . All rights reserved.

2984

Chen et al

Estradiol Regulates StAR and TSPO

2. Micevych P, Sinchak K, Mills RH, Tao L, LaPolt P, Lu JK. The luteinizing hormone surge is preceded by an estrogen-induced increase of hypothalamic progesterone in ovariectomized and adrenalectomized rats. Neuroendocrinology. 2003;78(1):29 –35. 3. Micevych P, Bondar G, Kuo J. Estrogen actions on neuroendocrine glia. Neuroendocrinology. 2010;91(3):211–222. 4. Paaske LK, Micevych PE, Sinchak K. Kisspeptin mediates neuroprogesterone induction of the luteinizing hormone surge. Paper presented at: 95th Annual Meeting of The Endocrine Society; June 15– 18, 2013; San Francisco, CA. 5. Micevych P, Sinchak K. Estradiol regulation of progesterone synthesis in the brain. Mol Cell Endocrinol. 2008;290(1–2):44 –50. 6. Micevych P, Sinchak K. Synthesis and function of hypothalamic neuroprogesterone in reproduction. Endocrinology. 2008;149(6): 2739 –2742. 7. Zwain IH, Yen SS. Neurosteroidogenesis in astrocytes, oligodendrocytes, and neurons of cerebral cortex of rat brain. Endocrinology. 1999;140(8):3843–3852. 8. Zwain IH, Arroyo A, Amato P, Yen SS. A role for hypothalamic astrocytes in dehydroepiandrosterone and estradiol regulation of gonadotropin-releasing hormone (GnRH) release by GnRH neurons. Neuroendocrinology. 2002;75(6):375–383. 9. Sinchak K, Mills RH, Tao L, LaPolt P, Lu JK, Micevych P. Estrogen induces de novo progesterone synthesis in astrocytes. Dev Neurosci. 2003;25(5):343–348. 10. Chaban VV, Lakhter AJ, Micevych P. A membrane estrogen receptor mediates intracellular calcium release in astrocytes. Endocrinology. 2004;145(8):3788 –3795. 11. Micevych P, Soma KK, Sinchak K. Neuroprogesterone: key to estrogen positive feedback? Brain Res Rev. 2008;57(2):470 – 480. 12. Kuo J, Hariri OR, Bondar G, Ogi J, Micevych P. Membrane estrogen receptor-alpha interacts with metabotropic glutamate receptor type 1a to mobilize intracellular calcium in hypothalamic astrocytes. Endocrinology. 2009;150(3):1369 –1376. 13. Kuo J, Hamid N, Bondar G, Prossnitz ER, Micevych P. Membrane estrogen receptors stimulate intracellular calcium release and progesterone synthesis in hypothalamic astrocytes. J Neurosci. 2010; 30(39):12950 –12957. 14. Itzhak Y, Baker L, Norenberg MD. Characterization of the peripheral-type benzodiazepine receptors in cultured astrocytes: evidence for multiplicity. Glia. 1993;9(3):211–218. 15. Papadopoulos V, Baraldi M, Guilarte TR, et al. Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci. 2006;27(8):402– 409. 16. Morohaku K, Pelton SH, Daugherty DJ, Butler WR, Deng W, Selvaraj V. Translocator protein/peripheral benzodiazepine receptor is not required for steroid hormone biosynthesis. Endocrinology. 2014;155(1):89 –97. 17. Dewing P, Christensen A, Bondar G, Micevych P. Protein kinase C signaling in the hypothalamic arcuate nucleus regulates sexual receptivity in female rats. Endocrinology. 2008;149(12):5934 –5942. 18. Li H, Degenhardt B, Tobin D, Yao ZX, Tasken K, Papadopoulos V. Identification, localization, and function in steroidogenesis of PAP7: a peripheral-type benzodiazepine receptor- and PKA (RIalpha)-associated protein. Mol Endocrinol. 2001;15(12):2211–2228. 19. Papadopoulos V, Miller WL. Role of mitochondria in steroidogenesis. Best Pract Res Clin Endocrinol Metab. 2012;26(6):771–790. 20. Manna PR, Soh JW, Stocco DM. The involvement of specific PKC isoenzymes in phorbol ester-mediated regulation of steroidogenic acute regulatory protein expression and steroid synthesis in mouse Leydig cells. Endocrinology. 2011;152(1):313–325. 21. Liu J, Rone MB, Papadopoulos V. Protein-protein interactions mediate mitochondrial cholesterol transport and steroid biosynthesis. J Biol Chem. 2006;281(50):38879 –38893. 22. Dyson MT, Kowalewski MP, Manna PR, Stocco DM. The differential regulation of steroidogenic acute regulatory protein-mediated

Endocrinology, August 2014, 155(8):2976 –2985

23.

24.

25.

26.

27.

28.

29. 30.

31.

32.

33.

34.

35.

36.

37.

38.

39.

40.

41.

42.

steroidogenesis by type I and type II PKA in MA-10 cells. Mol Cell Endocrinol. 2009;300(1–2):94 –103. Rone MB, Fan J, Papadopoulos V. Cholesterol transport in steroid biosynthesis: role of protein-protein interactions and implications in disease states. Biochim Biophys Acta. 2009;1791(7):646 – 658. Krsmanovic LZ, Mores N, Navarro CE, Tomi M, Catt KJ. Regulation of Ca2⫹-sensitive adenylyl cyclase in gonadotropin-releasing hormone neurons. Mol Endocrinol. 2001;15(3):429 – 440. Filardo EJ, Quinn JA, Frackelton AR Jr, Bland KI. Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol Endocrinol. 2002; 16(1):70 – 84. Dominguez R, Dewing P, Kuo J, Micevych P. Membrane-initiated estradiol signaling in immortalized hypothalamic N-38 neurons. Steroids. 2013; 78(6):607– 613. Cordey M, Gundimeda U, Gopalakrishna R, Pike CJ. Estrogen activates protein kinase C in neurons: role in neuroprotection. J Neurochem. 2003;84(6):1340 –1348. Chen C, Micevych P, Kuo J. Estradiol membrane signaling modulates the translocator protein (TSPO) via protein kinase A (PKA) pathway in hypothalamic astrocytes. Paper presented at: Society for Neuroscience 2013; November 9 –13, 2013; San Diego, CA. Bondar G, Kuo J, Hamid N, Micevych P. Estradiol-induced estrogen receptor-alpha trafficking. J Neurosci. 2009;29(48):15323–15330. McCarthy KD, de Vellis J. Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. J Cell Biol. 1980;85(3):890 –902. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25(4):402– 408. Micevych PE, Chaban V, Ogi J, Dewing P, Lu JK, Sinchak K. Estradiol stimulates progesterone synthesis in hypothalamic astrocyte cultures. Endocrinology. 2007;148(2):782–789. Kallen CB, Arakane F, Christenson LK, Watari H, Devoto L, Strauss JF 3rd. Unveiling the mechanism of action and regulation of the steroidogenic acute regulatory protein. Mol Cell Endocrinol. 1998; 145(1–2):39 – 45. Whalin ME, Boujrad N, Papadopoulos V, Krueger KE. Studies on the phosphorylation of the 18 kDa mitochondrial benzodiazepine receptor protein. J Recept Res. 1994;14(3– 4):217–228. Papadopoulos V, Brown AS. Role of the peripheral-type benzodiazepine receptor and the polypeptide diazepam binding inhibitor in steroidogenesis. J Steroid Biochem Mol Biol. 1995;53(1– 6):103– 110. Micevych P, Sinchak K. Temporal and concentration-dependent oestradiol effects on neural pathways mediating sexual receptivity. J Neuroendocrinol. 2013; 25(11):1012–1023. Gemzell-Danielsson K, Marions L. Mechanisms of action of mifepristone and levonorgestrel when used for emergency contraception. Hum Reprod Update. 2004;10(4):341–348. Kuo J, Hamid N, Bondar G, Dewing P, Clarkson J, Micevych P. Sex differences in hypothalamic astrocyte response to estradiol stimulation. Biol Sex Differ. 2010;1(1):7. Fares F, Bar-Ami S, Brandes JM, Gavish M. Changes in the density of peripheral benzodiazepine binding sites in genital organs of the female rat during the oestrous cycle. J Reprod Fertil. 1988;83(2): 619 – 625. Bar-Ami S, Amiri Z, Fares F, Gavish M. Modulation of peripheral benzodiazepine receptors in female rat genital organs by various gonadal steroids. Life Sci. 1994;54(25):1965–1975. Mazurika C, Veenman L, Weizman R, et al. Estradiol modulates uterine 18 kDa translocator protein gene expression in uterus and kidney of rats. Mol Cell Endocrinol. 2009;307(1–2):43– 49. Batarseh A, Papadopoulos V. Regulation of translocator protein 18 kDa (TSPO) expression in health and disease states. Mol Cell Endocrinol. 2010;327(1–2):1–12.

The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 22 March 2015. at 19:22 For personal use only. No other uses without permission. . All rights reserved.

doi: 10.1210/en.2013-1844

43. Sprengel R, Werner P, Seeburg PH, et al. Molecular cloning and expression of cDNA encoding a peripheral-type benzodiazepine receptor. J Biol Chem. 1989;264(34):20415–20421. 44. Soma KK, Alday NA, Hau M, Schlinger BA. Dehydroepiandrosterone metabolism by 3beta-hydroxysteroid dehydrogenase/Delta5-Delta4 isomerase in adult zebra finch brain: sex difference and rapid effect of stress. Endocrinology. 2004;145(4):1668 –1677. 45. Miller WL. Steroid hormone synthesis in mitochondria. Mol Cell Endocrinol. 2013;379(1–2):62–73. 46. Arakane F, King SR, Du Y, et al. Phosphorylation of steroidogenic acute regulatory protein (StAR) modulates its steroidogenic activity. J Biol Chem. 1997;272(51):32656 –32662. 47. Arakane F, Sugawara T, Nishino H, et al. Steroidogenic acute regulatory protein (StAR) retains activity in the absence of its mitochondrial import sequence: implications for the mechanism of StAR action. Proc Natl Acad Sci U S. A. 1996;93(24):13731–13736. 48. West LA, Horvat RD, Roess DA, Barisas BG, Juengel JL, Niswender GD. Steroidogenic acute regulatory protein and peripheral-type benzodiazepine receptor associate at the mitochondrial membrane. Endocrinology. 2001;142(1):502–505. 49. Hauet T, Yao ZX, Bose HS, et al. Peripheral-type benzodiazepine receptor-mediated action of steroidogenic acute regulatory protein on cholesterol entry into leydig cell mitochondria. Mol Endocrinol. 2005;19(2):540 –554. 50. Clark BJ, Wells J, King SR, Stocco DM. The purification, cloning, and expression of a novel luteinizing hormone-induced mitochondrial protein in MA-10 mouse Leydig tumor cells. Characterization of the steroidogenic acute regulatory protein (StAR). J Biol Chem. 1994;269(45):28314 –28322. 51. Epstein LF, Orme-Johnson NR. Regulation of steroid hormone biosynthesis. Identification of precursors of a phosphoprotein targeted to the mitochondrion in stimulated rat adrenal cortex cells. J Biol Chem. 1991;266(29):19739 –19745. 52. Stocco DM, Sodeman TC. The 30-kDa mitochondrial proteins induced by hormone stimulation in MA-10 mouse Leydig tumor cells are processed from larger precursors. J Biol Chem. 1991;266(29): 19731–19738. 53. Artemenko IP, Zhao D, Hales DB, Hales KH, Jefcoate CR. Mitochondrial processing of newly synthesized steroidogenic acute regulatory protein (StAR), but not total StAR, mediates cholesterol transfer to cytochrome P450 side chain cleavage enzyme in adrenal cells. J Biol Chem. 2001;276(49):46583– 46596. 54. Stocco DM, Clark BJ. Role of the steroidogenic acute regulatory protein (StAR) in steroidogenesis. Biochem Pharmacol. 1996;51(3): 197–205. 55. Furukawa A, Miyatake A, Ohnishi T, Ichikawa Y. Steroidogenic acute regulatory protein (StAR) transcripts constitutively expressed in the adult rat central nervous system: colocalization of StAR, cytochrome P-450SCC (CYP XIA1), and 3beta-hydroxysteroid dehydrogenase in the rat brain. J Neurochem. 1998;71(6):2231–2238. 56. King SR, Manna PR, Ishii T, et al. An essential component in steroid synthesis, the steroidogenic acute regulatory protein, is expressed in discrete regions of the brain. J Neurosci. 2002;22(24):10613– 10620. 57. Kim HJ, Park CH, Roh GS, Kang SS, Cho GJ, Choi WS. Changes of steroidogenic acute regulatory protein mRNA expression in postnatal rat development. Brain Res Dev Brain Res. 2002;139(2):247– 254. 58. Karri S, Dertien JS, Stocco DM, Syapin PJ. Steroidogenic acute regulatory protein expression and pregnenolone synthesis in rat astrocyte cultures. J Neuroendocrinol. 2007;19(11):860 – 869. 59. Braestrup C, Squires RF. Specific benzodiazepine receptors in rat

endo.endojournals.org

60.

61.

62.

63.

64.

65.

66.

67.

68.

69.

70.

71.

72.

73.

74.

75.

2985

brain characterized by high-affinity (3H)diazepam binding. Proc Natl Acad Sci U S A. 1977;74(9):3805–3809. Papadopoulos V. Peripheral-type benzodiazepine/diazepam binding inhibitor receptor: biological role in steroidogenic cell function. Endocr Rev. 1993;14(2):222–240. Jamin N, Neumann JM, Ostuni MA, et al. Characterization of the cholesterol recognition amino acid consensus sequence of the peripheral-type benzodiazepine receptor. Mol Endocrinol. 2005; 19(3):588 –594. Li H, Yao Z, Degenhardt B, Teper G, Papadopoulos V. Cholesterol binding at the cholesterol recognition/ interaction amino acid consensus (CRAC) of the peripheral-type benzodiazepine receptor and inhibition of steroidogenesis by an HIV TAT-CRAC peptide. Proc Natl Acad Sci U S A. 2001;98(3):1267–1272. Papadopoulos V, Amri H, Li H, Boujrad N, Vidic B, Garnier M. Targeted disruption of the peripheral-type benzodiazepine receptor gene inhibits steroidogenesis in the R2C Leydig tumor cell line. J Biol Chem. 1997;272(51):32129 –32135. Rupprecht R, Papadopoulos V, Rammes G, et al. Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nature reviews Drug discovery. 2010;9(12): 971–988. Rone MB, Midzak AS, Issop L, et al. Identification of a dynamic mitochondrial protein complex driving cholesterol import, trafficking, and metabolism to steroid hormones. Mol Endocrinol. 2012; 26(11):1868 –1882. Miller WL, Strauss JF 3rd. Molecular pathology and mechanism of action of the steroidogenic acute regulatory protein, StAR. J Steroid Biochem Mol Biol. 1999;69(1– 6):131–141. Miller WL, Auchus RJ. The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr Rev. 2011;32(1):81–151. Daugherty DJ, Selvaraj V, Chechneva OV, Liu XB, Pleasure DE, Deng W. A TSPO ligand is protective in a mouse model of multiple sclerosis. EMBO Mol Med. 2013;5(6):891–903. Ferzaz B, Brault E, Bourliaud G, et al. SSR180575 (7-chloro-N,N,5trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-b]indole-1 -acetamide), a peripheral benzodiazepine receptor ligand, promotes neuronal survival and repair. J Pharmacol Exp Ther. 2002;301(3):1067–1078. Barron AM, Garcia-Segura LM, Caruso D, et al. Ligand for translocator protein reverses pathology in a mouse model of Alzheimer’s disease. J Neurosci. 2013;33(20):8891– 8897. Costa B, Da Pozzo E, Martini C. Translocator protein as a promising target for novel anxiolytics. Curr Top Med Chem. 2012;12(4):270 – 285. Nothdurfter C, Baghai TC, Schüle C, Rupprecht R. Translocator protein (18 kDa) (TSPO) as a therapeutic target for anxiety and neurologic disorders. Eur Arch Psychiatry Clin Neurosci. 2012; 262(Suppl 2):S107–S112. Dell’Osso L, Da Pozzo E, Carmassi C, Trincavelli ML, Ciapparelli A, Martini C. Lifetime manic-hypomanic symptoms in post-traumatic stress disorder: relationship with the 18 kDa mitochondrial translocator protein density. Psychiatry Res. 2010;177(1–2):139 – 143. Gavish M, Laor N, Bidder M, et al. Altered platelet peripheral-type benzodiazepine receptor in posttraumatic stress disorder. Neuropsychopharmacology. 1996;14(3):181–186. Qiu ZK, Zhang LM, Zhao N, et al. Repeated administration of AC-5216, a ligand for the 18 kDa translocator protein, improves behavioral deficits in a mouse model of post-traumatic stress disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2013;45:40 – 46.

The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 22 March 2015. at 19:22 For personal use only. No other uses without permission. . All rights reserved.